Loading…
Loading…
EQT completes final sell-down in Galderma, a global dermatology company delivering science-backed solutions to healthcare professionals, consumers and patients
/PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce it has signed an agreement to
L'ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20% Clichy, December 8th, 2025 - L'Oréal today announces the acquisition of an additional 10% in Galderma Group AG from a consortium led by EQT, which includes Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte.
LE GROUPE L'OREAL ANNONCE LE RENFORCEMENT DE SON INVESTISSEMENT STRATEGIQUE DANS GALDERMA EN PRENANT 10% SUPPLEMENTAIRES ET DETENIR AINSI 20% DU CAPITAL Clichy, le 8 décembre 2025 - L'Oréal annonce aujourd'hui l'acquisition de 10 % supplémentaires de Galderma Group AG auprès d'un consortium mené par EQT comprenant Sunshine SwissCo GmbH (SSCO), Abu Dhabi Investment Authority (ADIA), et Auba Investment Pte.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for GALD.SW and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.